{"entity":{"id":"nct01482949","kind":"trial","name":"A Rollover Protocol for Subjects Previously Treated With AGS-003","aka":[],"tldr":"A phase 2 trial of Rocapuldencel-T run by Argos Therapeutics, terminated.","summary":"A Rollover Protocol for Subjects Previously Treated With AGS-003 is a phase 2 interventional study registered as NCT01482949 by Argos Therapeutics, with 2 participants enrolled, started 2011-09. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT01482949","url":"https://clinicaltrials.gov/study/NCT01482949"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["rocapuldencel-t"],"companies":["argos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01482949","phase":"2","setting":"A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006","sponsor":"Argos Therapeutics","enrolled":2,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01482949/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"rocapuldencel-t","kind":"drug","name":"Rocapuldencel-T","route":"/drugs/rocapuldencel-t/"}],"company":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/"}]}}